According to ScienceDaily, an international research team led by Professor Jang Hyun Choi at UNIST has identified a critical genetic factor driving metabolic-associated fatty liver disease. Their findings suggest that an already approved vitamin, specifically niacin or vitamin B3, could serve as an effective targeted therapy for the condition. This development addresses a significant gap in treatment options for the roughly 30% of the global population currently affected by the disorder.
The study pinpointed microRNA-93 as a central regulator within liver cells that controls specific gene activities for proper function. Researchers observed that levels of this molecule remained unusually high in both human patients with fatty liver disease and in animal models used for testing. This specific molecule drives fat accumulation and inflammation by suppressing SIRT1, a gene essential for managing fat metabolism inside liver cells.
To validate these findings, the team utilized gene editing techniques to stop the production of microRNA-93 in mice completely. These animals exhibited significantly less fat accumulation in their livers along with improved insulin sensitivity compared to control groups. Conversely, mice engineered to produce excess microRNA-93 experienced more severe metabolic issues within the liver tissue.
The researchers then screened 150 FDA-approved drugs to determine if any could effectively reduce microRNA-93 levels in the biological system. Niacin, commonly known as vitamin B3, stood out as the most effective option among the candidates tested during the comprehensive review. This screening process highlighted the potential for repurposing existing medications rather than developing entirely new compounds from scratch.
In mice treated with niacin, microRNA-93 levels dropped sharply while SIRT1 activity increased significantly within the tissue. This adjustment helped restore normal fat-processing pathways in the liver and improved overall lipid balance for the subjects. The findings suggest that modulating this specific pathway could offer high translational clinical relevance for future medical applications.
Professor Jang Hyun Choi stated that the study precisely elucidates the molecular origin of metabolic-associated fatty liver disease. He added that niacin holds promise as a candidate for combination therapies targeting microRNA pathways given its established safety profile. The researchers noted that it is a well-established medication currently used to treat hyperlipidemia in standard clinical practice.
This work was supported by several major organizations including the National Research Foundation of Korea and the Korea Research Institute of Bioscience and Biotechnology. The findings were published online in the journal Metabolism: Clinical and Experimental for peer review and scientific scrutiny. Key contributors included Dr. Yo Han Lee and Kieun Park from UNIST along with Professor Joonho Jeong from Ulsan University Hospital.
Metabolic-associated fatty liver disease impacts roughly 30% of people globally and has long lacked effective, targeted therapies for widespread use. Previous attempts to treat the condition often resulted in limited success rates or significant side effects for patients receiving care. This new approach offers a potential solution using a compound that is already widely available and cost-effective for distribution.
The identification of this genetic factor marks the first time this molecule has been clearly linked to how the disease develops and progresses over time. Scientists believe that repurposing an approved vitamin compound to modulate this pathway could accelerate the development of viable treatments significantly. This strategy reduces regulatory hurdles compared to novel drug development pipelines requiring extensive safety testing from the beginning.
Broader implications include the potential for immediate clinical trials to validate safety and efficacy in human subjects with the condition. Researchers warn that further studies are necessary to confirm dosage requirements and long-term outcomes for patients receiving the treatment. Watch for upcoming announcements regarding the next phase of clinical testing as the team moves forward with their investigation.
